Medicare Bridge Drugs vs. Compounded Alternatives: The Real Cost Comparison

⚡ TL;DR — OUR VERDICT

During the Bridge (July 2026–Dec 2027), brand-name at $50/month is the clear winner. But the Bridge is temporary. Patients who start on Bridge drugs need an exit strategy — either the BALANCE Model launches, Congress acts, or they transition to compounded alternatives. Starting with compounded at $99–$179/month costs more now but avoids the price cliff risk.

The Bridge Program: What $50 Actually Gets You

Starting July 1, 2026, the Medicare GLP-1 Bridge covers three medications at $50/month:

Foundayo (orforglipron) — all formulations
Wegovy (semaglutide) — injection and oral tablet
Zepbound KwikPen (tirzepatide) — KwikPen only (not vials or single-dose pens)

At $50/month, this is cheaper than any compounded alternative on the market. But there are significant caveats.

The Fine Print That Matters

Feature	Medicare Bridge	Compounded GLP-1
Monthly cost	$50 flat	$99–$299
Counts toward Part D deductible	❌ No	N/A
Counts toward $2,100 OOP cap	❌ No	N/A
Low-Income Subsidy applies	❌ No	N/A
Program end date	Dec 31, 2027	None — ongoing
Dose affects price	❌ $50 at any dose	⚠️ Often increases with dose
FDA-approved product	✅ Yes	❌ No
Prior authorization	✅ Required	❌ Not required

18-Month Cost Model

Scenario	Monthly	18-Month Total	After Dec 2027
Medicare Bridge	$50	$900	Unknown — retail could be $800–$1,300/mo
GobyMeds (compounded)	$99	$1,782	Continues at $99/mo
Embody (compounded)	$149–$299	$2,682–$5,382	Continues as-is
Gala (compounded)	$179	$3,222	Continues at $179/mo

The Exit Strategy Problem

The BALANCE Model — CMS's longer-term plan for Medicare GLP-1 coverage — was supposed to launch in Part D by January 2027. It didn't. Not enough insurance plans signed on. The Bridge was extended from 6 months to 18 months as a stopgap.

If the Bridge ends December 2027 and nothing replaces it, patients face a sudden transition from $50/month to full retail pricing. Most Medicare beneficiaries can't absorb $800–$1,300/month for medication. The options at that point:

Switch to compounded GLP-1 ($99–$299/month) — but you'll need to find a provider and restart the relationship
Manufacturer savings programs — NovoCare and LillyDirect may offer Medicare-specific pricing, but nothing is guaranteed post-Bridge
Stop medication — with the associated weight regain risk

Our Recommendation by Scenario

If you qualify for the Bridge and can afford $50/month

Start with the Bridge in July. Brand-name medications with FDA approval at $50/month is an extraordinary deal. But simultaneously research compounded providers as a backup. Know who you'd switch to if the Bridge ends.

If the $50 copay is a financial strain

The Bridge may not be your best option. Remember: the $50 doesn't count toward your Part D out-of-pocket cap, and Low-Income Subsidy doesn't apply. If you're on Extra Help and accustomed to $5–$10 copays, $50 is a meaningful increase. Compounded alternatives at $99/month may be more sustainable long-term.

If you're already on compounded GLP-1 and stable

You could switch to Bridge for the 18-month savings, then switch back to compounded after. The math saves ~$900–$3,500 over the Bridge period. But switching medications twice introduces transition risk. If you're stable and can afford your current program, staying put has its own value.

Compounded Alternatives

Budget Pick

GobyMeds

$99/mo

Semaglutide from $99/mo. No program expiration. LegitScript certified.

Compare →

Paid link · Compounded medications are not FDA-approved